These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39110316)

  • 1. Elafibranor: First Approval.
    Blair HA
    Drugs; 2024 Sep; 84(9):1143-1148. PubMed ID: 39110316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
    N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
    J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.
    Lin W; Wang JX; Liu YJ
    Syst Rev; 2024 Jan; 13(1):46. PubMed ID: 38287391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
    Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obeticholic Acid: First Global Approval.
    Markham A; Keam SJ
    Drugs; 2016 Aug; 76(12):1221-6. PubMed ID: 27406083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
    Ghonem NS; Auclair AM; Hemme CL; Gallucci GM; de la Rosa Rodriguez R; Boyer JL; Assis DN
    Clin Pharmacol Ther; 2020 Dec; 108(6):1213-1223. PubMed ID: 32480421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Rust C; Beuers U
    Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
    Zein CO; Lindor KD
    Curr Gastroenterol Rep; 2010 Feb; 12(1):13-22. PubMed ID: 20425480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.
    Caines A; Trudeau S; Gordon SC
    Expert Opin Pharmacother; 2024 Aug; 25(11):1517-1523. PubMed ID: 39107982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
    Ahn DW
    Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
    Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
    Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.